![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1374796
¼¼°èÀÇ Èä° ¹è¾× ±â±â ½ÃÀå(2023-2030³â)Global Thoracic Drainage Devices Market -2023-2030 |
ÃÖ¼Òħ½ÀÀû Èä° ¹è¾×¼úÀ» ¼±È£Çϴ ȯÀÚµéÀÇ ÃÖ¼Òħ½ÀÀû Èä° ¹è¾×¼ú·ÎÀÇ Àüȯ°ú °°Àº Ãß¼¼´Â ¼¼°è Èä° ¹è¾× ±â±â ½ÃÀåÀ» ÁÖµµÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¼¼°è Èä° ¹è¾× ±â±â ½ÃÀåÀº ÃÖ±Ù ¸î ³â µ¿¾È Å©°Ô ¼ºÀåÇØ ¿ÔÀ¸¸ç ¾ÕÀ¸·Îµµ °è¼Ó »ó½Â¼¼¸¦ À̾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½ÃÀåÀº º¯ÈÀÇ ½Ã±â¸¦ ¸ÂÀÌÇϰí ÀÖÀ¸¸ç, ȯÀÚÀÇ ½Ç½Ã°£ ¸ð´ÏÅ͸µ, ¿ø°Ý µ¥ÀÌÅÍ ¾×¼¼½º, ȯÀÚ °ü¸® °³¼±À» À§ÇÑ ¿¬°á ±â´ÉÀ» °®Ãá Èä° ¹è¾× ½Ã½ºÅÛÀÇ µðÁöÅÐÈ µî ¸î °¡Áö Áß¿äÇÑ Æ®·»µåÀÇ ¿µÇâÀ» ¹Þ°í ÀÖ½À´Ï´Ù.
¶ÇÇÑ, ÈäºÎ ÁúȯÀÇ À¯º´·ü Áõ°¡, Èä° ¹è¾× ±â±âÀÇ Áö¼ÓÀûÀÎ ±â¼ú ¹ßÀüÀ¸·Î ÀÎÇÑ È¿À²¼º ¹× ¾ÈÀü¼º Çâ»ó, Æó ÀýÁ¦¼ú ¹× ÀÌ½Ä µî ÈäºÎ ¼ö¼úÀÇ Áõ°¡·Î ÀÎÇØ Èä° ¹è¾× ±â±â°¡ ÇÊ¿äÇÑ ¼ö¼úÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Èä° ¹è¾× ±â±â ½ÃÀå ±Ô¸ð°¡ È®´ëµÇ°í ÀÖ½À´Ï´Ù. »õ·Î¿î ±â¼ú¿¡ ´ëÇÑ ¿¬±¸ Ȱµ¿ÀÌ È°¹ßÇØÁö°í, ATMOS MedizinTechnik GmbH & Co.K, Becton, Dickinson and Company ¹× ±âŸ ±â¾÷µéÀÌ ½ÃÀå¿¡¼ Ȱ¹ßÇÏ°Ô È°µ¿Çϰí ÀÖ´Â °Íµµ ºÏ¹Ì Áö¿ªÀÇ ¼ö¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ÀÖ½À´Ï´Ù.
ÈäºÎ ¼ö¼ú °Ç¼öÀÇ Áõ°¡´Â Èä° ¹è¾× ±â±â ½ÃÀåÀ» ÁÖµµÇÏ´Â Áß¿äÇÑ ¿äÀÎÀÔ´Ï´Ù. Èä° ¹è¾× ±â±â´Â ½É¸·°°ú È丷°¿¡¼ Ç÷¾×, ü¾× ¹× °ø±â¸¦ ¹èÃâÇÏ¿© ¼ö¼ú ÈÄ ¹®Á¦¸¦ ÁÙÀ̰í Èä¼ö, ŽÆ÷³ªµå, ±âÈä, ÃâÇ÷°ú °°Àº ¹®Á¦¸¦ ÃÖ¼ÒÈÇÒ ¼ö Àֱ⠶§¹®¿¡ ÈäºÎ ¿Ü°ú ¼ö¼ú¿¡ ÇʼöÀûÀÔ´Ï´Ù. °³¼±µÈ µðÁöÅÐ ¹è¾× ÀåÄ¡°¡ °³¹ßµÇ±â Àü¿¡´Â Áö³ 50³â µ¿¾È °íÀüÀûÀÎ 3½Ç ÈíÀιýÀÌ ÈäºÎ ¼ö¼úÀÇ Ç¥ÁØÀ̾ú½À´Ï´Ù.
¿¹¸¦ µé¾î, 2022³â ¹ßÇ¥µÈ ¹Ì±¹ ±¹¸³ÀÇÇеµ¼°ü ³í¹®¿¡ µû¸£¸é, ¹Ì±¹¿¡¼¸¸ ¾à 4,000¸íÀÇ ÈäºÎ¿Ü°ú Àǻ簡 ¿¬°£ ¾à 53¸¸ °ÇÀÇ ÀÏ¹Ý ÈäºÎ¿Ü°ú ¼ö¼úÀ» ½ÃÇàÇϰí ÀÖÀ¸¸ç, ´ëºÎºÐ ³²¼º(92%)À̸ç, Æò±Õ ¿¬·ÉÀº 56¼¼´Ù. Æò±Õ ÈäºÎ¿Ü°ú ÀÇ»ç´Â ¿¬°£ 135¸íÀÇ È¯ÀÚ¸¦ ¼ö¼úÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ÈäºÎ ¼ö¼úÀÇ Áõ°¡´Â ȯÀÚ Ä¡·á ¹× Ä¡·á °á°ú °³¼±¿¡ ´ëÇÑ ½ÃÀåÀÇ ¼ºÀå ÀáÀç·ÂÀ» °Á¶Çϰí ÀÖ½À´Ï´Ù.
°í±Þ ¼³°è¸¦ Æ÷ÇÔÇÏ´Â Èä° ¹è¾× ±â±âÀÇ ¹ßÀüÀÌ È®´ëµÇ¸é¼ ½ÃÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 9¿ù Merit Medical Systems, Inc.´Â Àç¹ß¼º ¹× Áõ»ó¼º Èä¼ö(Æó ¿ÜºÎ¿¡ °í¿© Àִ ü¾×)¿Í ¾Ç¼º º¹¼ö(¾ÏÀ¸·Î ÀÎÇØ º¹ºÎ¿¡ °í¿© Àִ ü¾×)¸¦ Ä¡·áÇÏ´Â µ¥ »ç¿ëµÇ´Â Aspira Evacuated Drainage BottleÀ» Ãâ½ÃÇÏ¿´½À´Ï´Ù. ¾ÏÀ¸·Î ÀÎÇØ º¹ºÎ¿¡ °í¿© Àִ ü¾×)ÀÇ Ä¡·á¿¡ »ç¿ëµË´Ï´Ù.
¶ÇÇÑ, ¾Æ½ºÇǶó ¹è¾× ½Ã½ºÅÛÀÇ ÀûÀÀÁõÀÎ Àç¹ß¼º Èä¼ö¿Í ¾Ç¼º º¹¼öÀÇ ¹è¾×Àº ¸ðµÎ º´¿ø ³» ¹è¾×ÀÌ ÇÊ¿äÇÑ °æ¿ì°¡ ¸¹À¸¸ç, ÀÌ´Â ÃÖ÷´Ü ¹è¾× ±â¼úÀÌ È¯ÀÚ Ä¡·á¿Í »îÀÇ ÁúÀ» Çâ»ó½ÃŰ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÑ´Ù´Â °ÍÀ» º¸¿©ÁÝ´Ï´Ù. µû¶ó¼ ´õ ¸¹Àº ÀÇ·á ±â°ü°ú Àü¹®°¡µéÀÌ ÃÖ÷´Ü ¼Ö·ç¼ÇÀ» äÅÃÇÔ¿¡ µû¶ó Èä° ¹è¾× ±â±â ½ÃÀåÀº ¿¹Ãø ±â°£ µ¿¾È È¿À²¼º, Á¤È®¼º ¹× ȯÀÚ °á°ú¸¦ °³¼±ÇÏ´Â ±â¼ú °³¼±¿¡ ÈûÀÔ¾î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¼÷·ÃµÈ Àü¹®°¡ÀÇ ºÎÁ·Àº ÀÌ ½ÃÀåÀÇ ÁÖ¿ä ¾ïÁ¦¿äÀÎÀÔ´Ï´Ù. Èä° ¹è¾×¼úÀº ´ÙÇÐÁ¦Àû Çù·ÂÀÌ ÇÊ¿äÇÑ °íµµÀÇ ¼ö¼úÀ̸ç, °£È£»ç´Â Èä°°ü »ðÀÔ ¹× °ü¸®¿¡¼ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ±×·¯³ª ·¹Áö´øÆ®°¡ »ðÀÔÇÏ´Â Èä°°ü¿¡´Â ¸¹Àº ¹®Á¦°¡ ÀÖ¾î Ãß°¡ ÈÆ·ÃÀÇ Çʿ伺ÀÌ °Á¶µÇ°í ÀÖ½À´Ï´Ù.
¶ÇÇÑ Èä°°ü »ðÀÔÀº ¹æ»ç¼±°ú ÀÇ»ç, Æó Àü¹®ÀÇ, ÈäºÎ¿Ü°ú Àǻ簡 ¼öÇàÇÏ´Â ÀϹÝÀûÀÎ ½Ã¼úÀÔ´Ï´Ù. ºÏ¹Ì¹æ»ç¼±ÇÐȸ(Radiological Society of North America) 2022¿¡ µû¸£¸é, À¯·´¿¡´Â Àα¸ 10¸¸ ¸í´ç 13¸íÀÇ ¹æ»ç¼±°ú Àü¹®Àǰ¡ ÀÖÁö¸¸ ¿µ±¹¿¡´Â Àα¸ 10¸¸ ¸í´ç 8.5¸í¿¡ ºÒ°úÇØ ¿µ±¹¿¡´Â ¹æ»ç¼±°ú Àü¹®Àǰ¡ ºÎÁ·ÇÕ´Ï´Ù. µû¶ó¼ ¿¹Ãø ±â°£ µ¿¾È ½ÃÀåÀÌ ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
The trend such as the shift towards minimal invasive thoracic drainage procedures driven by patient preference for less invasive techniques is expected to dominate the global thoracic drainage devices market.
The global thoracic drainage devices market has grown significantly in recent years and is projected to continue on its upward trend. The market is undergoing a transformational period, influenced by several significant trends such as digitalization in chest drainage systems equipped with connectivity features allowing real-time monitoring of patients, remote data access, and improved patient management.
Furthermore, the rising prevalence of thoracic diseases, Continuous technological advancements in thoracic drainage devices have improved their efficiency and safety and increasing number of thoracic surgeries, including lung resections and transplantations, that requires thoracic drainage devices for post-operative care are driving up the thoracic drainage devices market size. The growing research activities for new technologies and presence of establish pharmaceutical medtech companies are some of the factors in demand from North American regions. With significant competitors like ATMOS MedizinTechnik GmbH & Co. K, Becton, Dickinson and Company, and others actively operating in the market.
The increasing number of thoracic surgeries is an important factor driving in the market for thoracic drainage devices. These devices are essential in cardiothoracic surgery because they allow for the drainage of blood, fluids, and air from the pericardial and pleural cavities, reducing post-operative problems and minimizing concerns such as effusions, tamponade, pneumothoraces, and hemorrhage. Prior to the development of improved digital drainage devices, the classic 3-chamber suction technique was the standard in thoracic surgery for the past five decades.
For instance, according to a National Library of Medicine article published in 2022, states that about 530,000 general thoracic surgery cases are performed annually in the U.S alone by approximately 4,000 cardiothoracic surgeons, the majority of them are male (92%), with an average age of 56 years. The average thoracic surgeon performs 135 patients per year. This increase in thoracic procedures emphasizes the market's potential for growth in enhancing patient care and outcomes.
The growing advancements in thoracic drainage devices emcompassing advanced design is expected to drive the market. For instance, in September 2023, Merit Medical Systems, Inc. announced the launch of its Aspira Evacuated Drainage Bottle. The Aspira Drainage System is used to treat recurring and symptomatic pleural effusions (fluid buildup outside the lungs) and malignant ascites (fluid buildup in the abdomen caused by cancer).
Furthermore, the indications for the Aspira Drainage System for draining recurrent pleural effusions and malignant ascites, both of which frequently require in-hospital drainage, show the crucial role of cutting-edge drainage technologies in improving patient care and quality of life. Thus, as more healthcare organizations and professionals adopt cutting-edge solutions, the market for thoracic drainage devices is expected to grow, fueled by technological improvements that improve efficiency, precision, and patient outcomes over the forecast period.
The lack of availability of skilled professional is the major restraint for this market. Thoracic drainage is an advanced surgical procedure that requires interdisciplinary collaboration, and nurses play a significant role in chest tube insertion and care. However, chest tubes inserted by resident physicians are frequently associated with problems, emphasizing the need for further training.
Furthermore, chest tube insertion is a common procedure performed by radiologists, pulmonary specialists, and thoracic surgeons. According to the Radiological Society of North America 2022 article, there is a shortage of radiologists in the U.K, since Europe has 13 radiologists per 100,000 people, but the rate in the U.K. is only 8.5 per 100,000. Thus, owing to this factor the market is expected to grow over the forecast period.
The global thoracic drainage devices market is segmented based on product, material type, application, end user and region.
The chest drainage systems segment is expected to dominate the thoracic drainage device market. These systems are widely used in a variety of clinical settings, including cardiac surgery, cardiothoracic surgery, pulmonology, and critical care, to treat diseases such as pleural effusion, pneumothorax, hemothorax, and post-operative drainage.
This segment's is dominated due to the variety and effectiveness of chest drainage devices in removing air and fluids from the pleural area, hence aiding lung re-expansion and reducing problems. Furthermore, contemporary technological advancements in digital chest drainage systems, which allow for real-time monitoring and enhanced patient management, contribute to their widespread acceptability.
For instance, in July 2022, Centese, Inc. announced the first peer-reviewed study for its Thoraguard digital drainage system for cardiac surgery at Stanford University Medical Center, which was published in the Journal of Thoracic and Cardiovascular Surgery Open. Thoraguard is the first and only digital chest tube management system that delivers automated clog removal without human intervention while continuously and precisely monitoring vital physiological indicators to support clinical decision-making and enhance outcomes. Furthermore, when utilized during heart surgery, Thoraguard was demonstrated to be safe and efficacious when compared to standard analog chest tubes. Thus, owing to the above factors the segment is expected to dominate over the forecast period.
The increasing number of clinical trials in North America is expected to dominate the thoracic drainage device market. Clinical trials play a vital role in determining the safety and efficacy of novel devices. For instance, the University of Oklahoma is conducting a clinical trial comparing the Digital Chest Tube Drainage System (Thopaz + ) to the Analog in Pediatric Patients." The purpose of the research is to assess the efficacy of digital (Thopaz + ) and analog (Pleur-evac) drainage devices in pediatric patients. The trial is an interventional, randomized, and controlled study that is expected to enroll 140 people.
Furthermore, the study is expected to be finished by April 1, 2024 and there have been no prospective randomized controlled trials comparing digital versus analog chest tube drainage systems in pediatric patients so far. This will be the first prospective randomized trial to look into the possible benefits of adopting a digital chest tube drainage system in pediatric patients.
Moreover, the increasing prevalence of chronic diseases in North America is also expected to drive the market. Chronic diseases such as heart disease and pulmonology disease are significant drivers of demand for thoracic drainage devices. As the population ages and lifestyle factors increase the prevalence of chronic diseases, the need for appropriate thoracic drainage treatments grows. Thus, owing to the above factors the region is expected to dominate over the forecast period.
The major global players in the thoracic drainage devices market include: ATMOS MedizinTechnik GmbH & Co. K, Becton, Dickinson and Company, Cardinal Health., Cook Group Incorporated, Getinge AB, Sinapi Biomedical, Teleflex Incorporated, Utah Medical Products, Inc., Vygon SA, Sterimed Group, and among others.
The World Health Organization (WHO) reported more roughly 585.0 million confirmed COVID-19 cases as of August 2022, with around 6.4 million recorded deaths. However, research has shown that thoracic drainage systems play an important role in preventing the widespread development of COVID-19. Individuals with COVID-19 are at a higher risk of having acute respiratory distress syndrome (ARDS), which requires invasive mechanical ventilation.
Furthermore, COVID-19-related barotrauma frequently results in pneumothorax, necessitating chest tube insertion (thoracostomy). Furthermore, members of the German Health Alliance (GHA), which include prominent companies such as B. Braun, ATMOS MedizinTechnik GmbH & Co. KG, Getinge, and Drager, have seen a significant increase in global demand for their products, particularly thoracic drainage systems, since the beginning of 2020. ATMOS MedizinTechnik GmbH & Co. KG, for example, an innovative medical device maker, has increased production to meet increased demand, realizing that product categories such as drainage systems play a critical role in saving lives in the face of the COVID-19 epidemic.
The global thoracic drainage devices market report would provide approximately 53 tables, 54 figures and 195 Pages.
LIST NOT EXHAUSTIVE